Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Avexegen will use the NIH funds to develop an orally efficacious, NRG-4-based drug product with localized action in the gut and a superior safety profile.
Lead Product(s): Neuregulin-4-based therapy
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 15, 2021